Bo Cao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bo Cao has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Aili Zhang
School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China
3 shared publications Hongying Wang
School of Biomedical Engineering, Shanghai Jiao Tong University, No. 1954, Huashan Road, Xuhui District, Shanghai, China, Shanghai, Shanghai, 200030, China
1 shared publication- Hongzhi Xu
Department of Anesthesiology and Perioperative Medicine, Huashan Hospital Fudan University, No. 12, Middle Wulumuqi Road, Jing'an District, Shanghai, China, Shanghai, Shanghai, 200040, China
1 shared publication Jincheng Zou
School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, China
1 shared publicationLinyang Wei
School of Biomedical Engineering, Shanghai Jiao Tong University, No. 1954, Huashan Road, Xuhui District, Shanghai, China, Shanghai, Shanghai, 200030, China
1 shared publicationMing Xu
Department of Anaesthesiology, Huashan Hospital Fudan University, No. 12, Middle Wulumuqi Road, Jing'an District, Shanghai, China, Shanghai, Shanghai, 200040, China
1 shared publication
Latest Publications
- 9 April 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (8)
Electrothermal decoupling for investigating tumor treating fields of glioblastoma
Objective: Tumor Treating Fields (TTFields), a non-invasive cancer therapy employing low-intensity alternating electric fields to inhibit cancer cell division, has been used to treat glioblastoma. While clinically established for glioblastoma, the biological contribution of the intrinsic mild hyperthermia (iMH) remains not fully elucidated, limiting mechanistic clarity and treatment optimization. Approach: This study presents a precision in vitro platform designed to decouple the electrical and thermal components of TTFields (230 kHz, 2 V/cm). Based on numerical simulations, the platform utilizes a defined monitoring area to ensure field uniformity and an active thermodynamic compensation protocol to isolate electric and thermal modalities. Main results: Results indicated that the electric field primarily inhibited cell proliferation (32.0% reduction) and migration, whereas the iMH was the primary mediator of cytotoxicity and apoptosis. Notably, the combined electrothermal treatment exhibited a synergistic anti-tumor effect exceeding the additive effects of individual modalities. Significance: These findings suggest that the iMH component of TTFields functions as a therapeutic sensitizer rather than a side effect, offering a basis for optimizing future GBM treatment strategies.
- 9 April 2026
- Published by IOP Publishing in Physics in Medicine & Biology
- Vol. 71 (8)
Electrothermal decoupling for investigating tumor treating fields of glioblastoma
Objective: Tumor Treating Fields (TTFields), a non-invasive cancer therapy employing low-intensity alternating electric fields to inhibit cancer cell division, has been used to treat glioblastoma. While clinically established for glioblastoma, the biological contribution of the intrinsic mild hyperthermia (iMH) remains not fully elucidated, limiting mechanistic clarity and treatment optimization. Approach: This study presents a precision in vitro platform designed to decouple the electrical and thermal components of TTFields (230 kHz, 2 V/cm). Based on numerical simulations, the platform utilizes a defined monitoring area to ensure field uniformity and an active thermodynamic compensation protocol to isolate electric and thermal modalities. Main results: Results indicated that the electric field primarily inhibited cell proliferation (32.0% reduction) and migration, whereas the iMH was the primary mediator of cytotoxicity and apoptosis. Notably, the combined electrothermal treatment exhibited a synergistic anti-tumor effect exceeding the additive effects of individual modalities. Significance: These findings suggest that the iMH component of TTFields functions as a therapeutic sensitizer rather than a side effect, offering a basis for optimizing future GBM treatment strategies.
- 3 March 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Electromagnetics, RF and Microwaves in Medicine and Biology
- Vol. 10 (2) , 225-234
Development and Experimental Validation of a High-Precision Voltage and Power-Controlled Radiofrequency Ablation System
To design and validate a real-time precision control system for radiofrequency ablation (RFA) that counteracts power instability from dynamic tissue impedance, ensuring accurate and predictable energy delivery.An integrated system was developed with high-precision RF signal acquisition and two novel algorithms: an impedance-adaptive voltage correction to eliminate measurement errors, and a Taylor series-based feedforward control for rapid ($< $ 50ms) power adjustments. Performance was validated using an electrosurgical analyzer (20-500 $\Omega$ load range) and through ex vivo ablation experiments on porcine liver, chicken breast, and pork tissues.The system achieved high measurement accuracy, with voltage/current errors $< $ 3% and impedance/power errors $< $ 4%. The impedance-adaptive algorithm reduced voltage control error by 90% under non-nominal loads. Ex vivo ablations demonstrated excellent lesion repeatability, with ablation zone area discrepancies under 1.24%. The integrated hardware-software solution provides a validated method to enhance the predictability and consistency of RFA. Ensuring consistent RFA energy delivery, this technology creates predictable ablation zones, enhancing efficacy and safety by reducing tumor recurrence and minimizing damage to surrounding healthy tissue.
- 3 March 2026
- Published by Institute of Electrical and Electronics Engineers (IEEE) in IEEE Journal of Electromagnetics, RF and Microwaves in Medicine and Biology
- Vol. 10 (2) , 225-234
Development and Experimental Validation of a High-Precision Voltage and Power-Controlled Radiofrequency Ablation System
To design and validate a real-time precision control system for radiofrequency ablation (RFA) that counteracts power instability from dynamic tissue impedance, ensuring accurate and predictable energy delivery.An integrated system was developed with high-precision RF signal acquisition and two novel algorithms: an impedance-adaptive voltage correction to eliminate measurement errors, and a Taylor series-based feedforward control for rapid ($< $ 50ms) power adjustments. Performance was validated using an electrosurgical analyzer (20-500 $\Omega$ load range) and through ex vivo ablation experiments on porcine liver, chicken breast, and pork tissues.The system achieved high measurement accuracy, with voltage/current errors $< $ 3% and impedance/power errors $< $ 4%. The impedance-adaptive algorithm reduced voltage control error by 90% under non-nominal loads. Ex vivo ablations demonstrated excellent lesion repeatability, with ablation zone area discrepancies under 1.24%. The integrated hardware-software solution provides a validated method to enhance the predictability and consistency of RFA. Ensuring consistent RFA energy delivery, this technology creates predictable ablation zones, enhancing efficacy and safety by reducing tumor recurrence and minimizing damage to surrounding healthy tissue.
- Open Access
- 15 September 2022
- Published by MDPI AG in Bioengineering
- Vol. 9 (9) , 474
Synergetic Thermal Therapy for Cancer: State-of-the-Art and the Future
As a safe and minimal-invasive modality, thermal therapy has become an effective treatment in cancer treatment. Other than killing the tumor cells or destroying the tumor entirely, the thermal modality results in profound molecular, cellular and biological effects on both the targeted tissue, surrounding environments, and even the whole body, which has triggered the combination of the thermal therapy with other traditional therapies as chemotherapy and radiation therapy or new therapies like immunotherapy, gene therapy, etc. The combined treatments have shown encouraging therapeutic effects both in research and clinic. In this review, we have summarized the outcomes of the existing synergistic therapies, the underlying mechanisms that lead to these improvements, and the latest research in the past five years. Limitations and future directions of synergistic thermal therapy are also discussed.
- 15 September 2022
- Published by MDPI AG in Bioengineering
- Vol. 9 (9) , 474
Open AccessSynergetic Thermal Therapy for Cancer: State-of-the-Art and the Future
As a safe and minimal-invasive modality, thermal therapy has become an effective treatment in cancer treatment. Other than killing the tumor cells or destroying the tumor entirely, the thermal modality results in profound molecular, cellular and biological effects on both the targeted tissue, surrounding environments, and even the whole body, which has triggered the combination of the thermal therapy with other traditional therapies as chemotherapy and radiation therapy or new therapies like immunotherapy, gene therapy, etc. The combined treatments have shown encouraging therapeutic effects both in research and clinic. In this review, we have summarized the outcomes of the existing synergistic therapies, the underlying mechanisms that lead to these improvements, and the latest research in the past five years. Limitations and future directions of synergistic thermal therapy are also discussed.